Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03801590
Other study ID # infectious keratitis
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date January 1, 2023

Study information

Verified date July 2021
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Microbial keratitis is an infection of the cornea that is associated with risk of permanent visual impairment. It can be caused by bacteria, virus, fungus, protozoa and parasites. The common risk factors for infectious keratitis include ocular trauma, contact lens wear, recent ocular surgery, preexisting ocular surface disease, dry eyes, lid deformity, corneal sensation impairment, chronic use of topical steroids and systemic immunosuppression .


Description:

The spectrum of bacterial keratitis can also be influenced by geographic and climatic factors. The treatment usually consist of Topical administered antibiotics .the emergence of multidrug-resistant bacteria is a concern that might complicate the treatment and cure of infectious keratitis. Collagen cross linking (CXL) using ultraviolet-A (UV-A) and riboflavin in a treatment that was developed to increase the biochemical strength of the cornea The procedure is based on using riboflavin as a photosensitizer, which generates reactive oxygen species when activated by UV-A at 365 or370 nm. The standard technique (epi-off) also called Dresden Protocol includes removal of the epithelium in order to expose the underlying stroma to riboflavin, which is otherwise incompletely absorbed by the epithelium because of tight junctions. The area of corneal epithelium removed has a diameter of 6.0 to 8.5 mm. A crosslinking procedure without epithelial removal could also be performed (epi-on). It would likely be less painful compared to the standard procedure. The crosslinking process generates reactive oxygen species that can damage the cell walls of pathogens. CXL induces formation of new covalent bonds thereby rendering the corneal stroma biomechanically stronger and more resistant to enzymatic digestion . This can potentially limit the spread of infection. Furthermore, CXL-induced apoptosis could contribute to the reduction of inflammatory response during corneal infection .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date January 1, 2023
Est. primary completion date January 1, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with proved bacterial, fungal, acanthamoeba microbial keratitis . - Patient willing to comply with all study procedures . Exclusion Criteria: - Severe corneal scarring or opacification . - Patients with viral infectious keratitis - Prior herpetic infections . - Patients with any coexisting ocular pathology,ocular surface disease . - Patients with Autoimmune disease. - Pregnant women . - Corneal Thickness of less than 400 microns .

Study Design


Intervention

Device:
Crosslinking with Riboflavin and UV-A
the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (2)

Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008 Jan;27(1):22-7. doi: 10.1097/ICO.0b013e318156caf2. — View Citation

Jankov Ii MR, Jovanovic V, Nikolic L, Lake JC, Kymionis G, Coskunseven E. Corneal collagen cross-linking. Middle East Afr J Ophthalmol. 2010 Jan;17(1):21-7. doi: 10.4103/0974-9233.61213. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the duration for corneal ulcer healing By follow up with photography before crosslinking and one week after performing cxl. one year
See also
  Status Clinical Trial Phase
Completed NCT04030403 - Investigation of the Microbiome of the Cornea in Microbial Keratitis
Completed NCT04213313 - Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis
Recruiting NCT02570321 - Cross-linking for Corneal Ulcers Treatment Trial Phase 4
Terminated NCT00912509 - Cross Linking for Treatment of Corneal Infection N/A
Completed NCT01831206 - Collagen Cross-linking in Infectious Keratitis Trial Phase 2
Completed NCT04383431 - Cross-linking as Treatment in Infectious Keratitis N/A
Recruiting NCT05888987 - Use of a New Method for the Microbiological Diagnosis of Severe Corneal Infection
Recruiting NCT06364878 - Non-invasive Diagnostics of Microbial Keratitis
Completed NCT01739673 - Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis N/A
Completed NCT02819232 - Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs N/A